E
TNF Pharmaceuticals, Inc. TNFA
$0.19 -$0.0066-3.36% NASDAQ
Recommendation
Prev Close
$0.19
Volume
1,234,724
Avg Vol (90D)
1,192,055
Market Cap
$1.93M
Dividend & Yield
--
52-Week Range
$0.1615 - $2.60
P/E (TTM)
--
EPS (TTM)
-$11.88
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules
5/9/2025 - TipRanks Financial Blog
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for ...
5/8/2025 - GuruFocus
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for ...
5/8/2025 - GuruFocus
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
5/8/2025 - Business Wire
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish
4/22/2025 - Stocktwits News Feed
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development TNFA Stock News
4/22/2025 - GuruFocus
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
4/22/2025 - GuruFocus
TNF Pharmaceuticals, Renova Health partner using AI for drug development
4/22/2025 - The Fly
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
4/22/2025 - Business Wire
Contrasting TNF Pharmaceuticals (NASDAQ:TNFA) & Intellia Therapeutics (NASDAQ:NTLA)
4/19/2025 - Ticker Report
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at ...
4/16/2025 - GuruFocus
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at ...
4/16/2025 - GuruFocus
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Societys Spring Meeting 2025
4/16/2025 - Business Wire
Head to Head Contrast: TNF Pharmaceuticals (NASDAQ:TNFA) and Cardio Diagnostics (NASDAQ:CDIO)
3/29/2025 - Ticker Report
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier ...
3/17/2025 - GuruFocus
TNF Pharmaceuticals presents isomyosamine data
3/17/2025 - TipRanks Financial Blog
TNF Pharmaceuticals presents isomyosamine data
3/17/2025 - The Fly
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
3/17/2025 - Business Wire
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific ...
3/5/2025 - GuruFocus
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
3/5/2025 - Business Wire
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
2/25/2025 - GuruFocus
TNF Pharmaceuticals initiates isomyosamine trial
2/25/2025 - The Fly
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
2/25/2025 - Business Wire
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 ...
1/29/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$8.66M
Net Income (TTM)
-$23.36M
Balance Sheet
Total Assets (Q)
$21.42M
Total Debt (Q)
$10.60K
Total Liabilities (Q)
$6.70M
Book Value Per Share (Q)
$2.87
Cash Flow
Cash from Operations (TTM)
-$8.98M
Cash from Investing (TTM)
-$6.10M
Cash from Financing (TTM)
$12.57M
Net Change in Cash (TTM)
-$2.51M
Filings
Filing Date
Friday, April 11, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.12
7-Day Total Return
-5.52%
30-Day Total Return
-47.22%
60-Day Total Return
-66.53%
90-Day Total Return
-83.48%
Year to Date Total Return
-83.48%
1-Year Total Return
-92.40%
2-Year Total Return
-99.66%
3-Year Total Return
-99.79%
5-Year Total Return
--
52-week Low
Apr 21, 2025 - $0.1615
52-week High
May 13, 2024 - $2.60
Valuation
Market Cap
$1.93M - Nano Cap
Enterprise Value
-$1.51M
Price/Sales (TTM)
--
Price/Book (Q)
0.07
Dividends and Shares
Shares Outstanding
2.88M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
tnfpharma.com
Phone Number
856 848 8698
Address
1185 Avenue of the Americas
New York, NY 10036
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms... more
NASDAQ 05/09/2025 4:00PM Eastern Quotes delayed